Antiangiogenesis: A possible treatment option for prostate cancer?

Ritchie L. Longoria, Michael C. Cox, William D. Figg*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


With a need for effective treatment modalities in prostate cancer, angiogenesis is a likely target for the interference of tumor progression. Angiogenesis promotes the vasculature of a tumor, allowing for tumor progression and for cancer cells to metastasize and spread throughout the circulatory system. To date, there are > 20 antiangiogenic drugs undergoing preclinical and clinical investigation alone and in conjunction with other treatment options to determine the validity of antiangtogenic agents in the treatment of prostate cancer. This article reviews several aspects of antiangiogenesis and its relationship to the treatment of prostate cancer.

Original languageEnglish
Pages (from-to)197-202
Number of pages6
JournalClinical Genitourinary Cancer
Issue number3
StatePublished - Dec 2005
Externally publishedYes


  • Bevacizumab
  • Cetuximab
  • Marimastat
  • Matrix metalloproteinase
  • Thalidomide
  • Vascular endothelial growth factor


Dive into the research topics of 'Antiangiogenesis: A possible treatment option for prostate cancer?'. Together they form a unique fingerprint.

Cite this